Kansai Nerolac - Results Reviews - Weakest Among Peers; Pain Seems Priced In
Kansai Nerolac’s (KNPL) standalone revenue, at 6.2% YoY (INR14.1bn, 3-year CAGR: 8%), was largely in line. In decorative segment, volume declined 7...
244 Views
Kansai Nerolac - Weakest Among Peers; Pain Seems Priced In
Kansai Nerolac’s (KNPL) standalone revenue, at 6.2% YoY (INR14.1bn, 3-year CAGR: 8%), was largely in line. In decorative segment, volume declined 7...
205 Views
S&P BSE Indices: No Changes for SENSEX; 7 ADDs/DELs for BSE 100 in June 2022
S&P BSE Index changes for June 2022 were announced last week. No changes for SENSEX. 7 Adds/Deletes for BSE 100 including some negative and...
500 Views
Consumer Discretionary - Margin Recovery to Lag that in Topline
Recovery trends in discretionary categories are healthy: Our discretionary universe is expected to clock 11/2% revenue/EBITDA growth YoY (partly...
235 Views
Consumer Discretionary Margin Recovery to Lag that in Topline
Recovery trends in discretionary categories are healthy; Our discretionary universe is expected to clock 11/2% revenue/EBITDA growth YoY (partly...
312 Views